The stipulation expressly covers ‘any and all of the parties’ claims and counterclaims’ — meaning Vizgen’s invalidity or non-infringement counterclaims are also extinguished with prejudice alongside plaintiffs’ infringement claims. The mutual cost-bearing clause removes any inference of a prevailing party. Because this is a district court stipulated dismissal rather than an appellate ruling, no standard of review applies and no merits findings were recorded. The breadth of the ‘any and all’ language confirms a clean, bilateral exit with no surviving claims in this docket.

Any company developing or commercialising in situ spatial transcriptomics platforms, RNA mapping instruments, or spatial gene-expression workflows should treat US11293051B2, US11293054B2, US11021737B2, US11299767B2, and US11293052B2 as high-priority FTO targets. The case history shows 10X Genomics is prepared to litigate this portfolio aggressively in Delaware, and no public claim construction limits the apparent scope. Lab services and workflow providers — not just instrument manufacturers — were explicitly accused, widening the exposure footprint.

PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their spatial transcriptomics workflows against each of these five patent families simultaneously, identify claim-level overlap, and surface prior art relevant to validity challenges. Given the absence of any public Markman record from this case, Eureka’s claim analysis tools provide a structured basis for design-around assessment and IPR petition scoping — critical steps before any spatial genomics product launch or commercial scale-up.